Abstract
A proportion of EGFR-mutant and ALK-rearranged lung cancers do not respond to tyrosine kinase inhibition for as-yet unknown reasons. The BH3-only Bcl-2 family member BIM has been implicated as a potential biomarker of clinical benefit from kinase inhibitors. Quantifying BIM expression in tumor samples of patients with lung cancer may help to predict outcome, and potentially to guide therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
